Loading clinical trials...
Loading clinical trials...
A Phase Ib, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study of the Clinical Effect, Safety and Tolerability of a Single Intravenous Infusion of GSK1070806 in Moderate to Severe Atopic Dermatitis Patients
Conditions
Interventions
GSK1070806
Placebo
Locations
11
United States
GSK Investigational Site
North Little Rock, Arkansas, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Tampa, Florida, United States
GSK Investigational Site
Troy, Michigan, United States
GSK Investigational Site
Oklahoma City, Oklahoma, United States
GSK Investigational Site
Philadelphia, Pennsylvania, United States
Start Date
November 18, 2021
Primary Completion Date
December 19, 2022
Completion Date
March 13, 2023
Last Updated
August 28, 2025
NCT06488742
NCT05250115
NCT03563066
NCT04011215
NCT05177744
NCT06747897
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions